Aim This open-label, randomized, and multicentre trial tested the hypothesis that, on a
background of aspirin, continuing clopidogrel would be superior to stopping clopidogrel at …

Background In patients receiving aspirin, the optimal duration of clopidogrel therapy after
drug-eluting stent (DES) implantation remains unclear. Methods This multicentre …

ContextRecent studies of drug-eluting intracoronary stents suggest that current antiplatelet
regimens may not be sufficient to prevent late stent thrombosis. ObjectiveTo assess the …

BACKGROUND: Little is known about the association between clopidogrel use and long-
term outcomes after stent implantation for acute coronary syndromes (ACS) in clinical …

BACKGROUND: Concern regarding the rate of delayed acute stent thrombosis associated
with drug-eluting stent (DES) treatment has resulted in upward revision of the advised …

The risk of late thrombotic events and the need for prolonged dual antiplatelet therapy
detract from the clinical advantage offered by drug-eluting stents (DESs). Short-term studies …

Background: Long-term outcomes of antiplatelet monotherapy in patients who receive
percutaneous coronary intervention are unknown. The HOST-EXAM (Harmonizing Optimal …

Four weeks' therapy with clopidogrel, in addition to aspirin (acetylsalicylic acid), is currently
standard care after percutaneous coronary intervention (PCI) with stent implantation. The …

Objectives: The purpose of this study was to evaluate the risk of stent thrombosis (ST),
clinical outcomes, and the benefits of extended clopidogrel use after drug-eluting stent …

Background—Studies suggest that extended clopidogrel use after drug-eluting stent (DES)
implantation may decrease the risk of myocardial infarction (MI) and death. Little is known …